
8 REFERENCES

1. Abbas, A.T., Lichtman, A.H., Pillai, S., *Cellular and molecular immunology*. 6 ed. 2007, Philadelphia: Saunders Elsevier. 572.
2. Mosser, D.M. and J.P. Edwards, *Exploring the full spectrum of macrophage activation*. *Nat Rev Immunol*, 2008. **8**(12): p. 958-969.
3. Mellado, M., Rodríguez-Frade, J. M., Mañes, S., Martínez-A., C., *Chemokine Signaling and Functional Responses: The Role of Receptor Dimerization and TK Pathway Activation*. *Annual Review of Immunology*, 2001. **19**(1): p. 397.
4. Blanpain, C., *et al.*, *CCR5 and HIV infection*. *Receptors Channels*, 2002. **8**(1): p. 19-31.
5. Luster, A.D., *Chemokines--chemotactic cytokines that mediate inflammation*. *N Engl J Med*, 1998. **338**(7): p. 436-45.
6. Rot, A. and U.H. von Andrian, *Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells*. *Annu Rev Immunol*, 2004. **22**: p. 891-928.
7. Bronte, V. and P. Zanovello, *Regulation of immune responses by L-arginine metabolism*. *Nat Rev Immunol*, 2005. **5**(8): p. 641-54.
8. Fischereder, M., *et al.*, *CC chemokine receptor 5 and renal-transplant survival*. *Lancet*, 2001. **357**(9270): p. 1758-61.
9. Murphy, P.M., *et al.*, *International union of pharmacology. XXII. Nomenclature for chemokine receptors*. *Pharmacol Rev*, 2000. **52**(1): p. 145-76.
10. Miloslav, N., Jirat, J., Kosata, B., *IUPAC Compendium of Chemical Terminology (Gold Book)*. 2008.
11. Baucke, F., *New IUPAC recommendations on the measurement of pH - background and essentials*. *Analytical and Bioanalytical Chemistry*, 2002. **374**(5): p. 772-777.
12. Oppenheim, J.J., Feldmann, M., Durum, S. K., Hirano, T., Vilcek, J., Nicola, N. A., *Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense*. Online Database ed. 2000: Academic Press (a Harcourt Science and Technology Company). 2260.
13. Bult, C.J., *et al.*, *The Mouse Genome Database (MGD): mouse biology and model systems*. *Nucleic Acids Res*, 2008. **36**(Database issue): p. D724-8.
14. Zlotnik, A. and O. Yoshie, *Chemokines: a new classification system and their role in immunity*. *Immunity*, 2000. **12**(2): p. 121-7.
15. Rossi, D. and A. Zlotnik, *The biology of chemokines and their receptors*. *Annu Rev Immunol*, 2000. **18**: p. 217-42.
16. Ansel, K.M. and J.G. Cyster, *Chemokines in lymphopoiesis and lymphoid organ development*. *Current Opinion in Immunology*, 2001. **13**(2): p. 172-179.
17. Fernandez, E.J. and E. Lolis, *Structure, function, and inhibition of chemokines*. *Annual Review of Pharmacology and Toxicology*, 2002. **42**(1): p. 469-499.
18. Oppermann, M., *Chemokine receptor CCR5: insights into structure, function, and regulation*. *Cellular Signalling*, 2004. **16**(11): p. 1201-1210.
19. Petkovic, V., *et al.*, *I-TAC/CXCL11 is a natural antagonist for CCR5*. *J Leukoc Biol*, 2004. **76**(3): p. 701-8.
20. Loetscher, P., *et al.*, *The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*. *J. Biol. Chem.*, 2001. **276**(5): p. 2986-2991.
21. McQuibban, G.A., *et al.*, *Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo*. *Blood*, 2002. **100**(4): p. 1160-7.
22. Berahovich, R.D., *et al.*, *Proteolytic activation of alternative CCR1 ligands in inflammation*. *J Immunol*, 2005. **174**(11): p. 7341-51.

23. Mellado, M., *et al.*, *Chemokine receptor homo- or heterodimerization activates distinct signaling pathways*. EMBO J, 2001. **20**(10): p. 2497-507.
24. El-Asmar, L., *et al.*, *Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers*. Mol Pharmacol, 2005. **67**(2): p. 460-9.
25. Springael, J.Y., E. Urizar, and M. Parmentier, *Dimerization of chemokine receptors and its functional consequences*. Cytokine Growth Factor Rev, 2005. **16**(6): p. 611-23.
26. Springael, J.Y., *et al.*, *Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers*. Mol Pharmacol, 2006. **69**(5): p. 1652-61.
27. Yang, D., *et al.*, *Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6*. Science, 1999. **286**(5439): p. 525-8.
28. Yang, D., *et al.*, *Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense*. Annu Rev Immunol, 2004. **22**: p. 181-215.
29. Nakayama, T., *et al.*, *Liver-expressed chemokine/CC chemokine ligand 16 attracts eosinophils by interacting with histamine H4 receptor*. J Immunol, 2004. **173**(3): p. 2078-83.
30. Chen, C., *et al.*, *Heterodimerization and cross-desensitization between the [mu]-opioid receptor and the chemokine CCR5 receptor*. European Journal of Pharmacology, 2004. **483**(2-3): p. 175-186.
31. AbdAlla, S., H. Lothar, and U. Quitterer, *AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration*. Nature, 2000. **407**(6800): p. 94-8.
32. Isik, N., D. Hereld, and T. Jin, *Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors*. PLoS ONE, 2008. **3**(10): p. e3424.
33. Springael, J.-Y., *et al.*, *Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers*. Mol Pharmacol, 2006. **69**(5): p. 1652-1661.
34. Gao, J.L., *et al.*, *Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor*. J Exp Med, 1993. **177**(5): p. 1421-7.
35. Gao, J.L. and P.M. Murphy, *Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor*. J Biol Chem, 1994. **269**(46): p. 28539-42.
36. Billstrom, M.A., *et al.*, *Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection*. J. Virol., 1998. **72**(7): p. 5535-5544.
37. O'Dowd, B.F., *et al.*, *Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor*. J Biol Chem, 1989. **264**(13): p. 7564-9.
38. Murdoch, C. and A. Finn, *Chemokine receptors and their role in inflammation and infectious diseases*. Blood, 2000. **95**(10): p. 3032-3043.
39. Gao, J.-L., *et al.*, *Impaired Host Defense, Hematopoiesis, Granulomatous Inflammation and Type 1-Type 2 Cytokine Balance in Mice Lacking CC Chemokine Receptor 1*. J. Exp. Med., 1997. **185**(11): p. 1959-1968.
40. Baggiolini, M., *Chemokines and leukocyte traffic*. Nature, 1998. **392**(6676): p. 565-8.
41. Amin, K., *et al.*, *CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma*. J Allergy Clin Immunol, 2005. **116**(6): p. 1383-6.
42. Maghazachi, A.A., *G protein-coupled receptors in natural killer cells*. J Leukoc Biol, 2003. **74**(1): p. 16-24.
43. Shang, X., *et al.*, *Chemokine receptor 1 knockout abrogates natural killer cell recruitment and impairs type-1 cytokines in lymphoid tissue during pulmonary granuloma formation*. Am J Pathol, 2000. **157**(6): p. 2055-63.
44. Furuichi, K., *et al.*, *Chemokine Receptor CCR1 Regulates Inflammatory Cell Infiltration after Renal Ischemia-Reperfusion Injury*. J Immunol, 2008. **181**(12): p. 8670-8676.

45. Kaufmann, A., et al., *Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages*. J Leukoc Biol, 2001. **69**(2): p. 248-52.
46. Varani, S., et al., *Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5*. J Leukoc Biol, 2005. **77**(2): p. 219-228.
47. Sato, K., et al., *CC Chemokine Receptors, CCR-1 and CCR-3, Are Potentially Involved in Antigen-Presenting Cell Function of Human Peripheral Blood Monocyte-Derived Dendritic Cells*. Blood, 1999. **93**(1): p. 34-42.
48. Jugdé, F., et al., *Regulation by allergens of chemokine receptor expression on in vitro-generated dendritic cells*. Toxicology, 2005. **212**(2-3): p. 227-238.
49. Caux, C., et al., *Dendritic cell biology and regulation of dendritic cell trafficking by chemokines*. Springer Semin Immunopathol, 2000. **22**(4): p. 345-69.
50. Su, S.-b., et al., *Inhibition of Immature Erythroid Progenitor Cell Proliferation by Macrophage Inflammatory Protein-1alpha by Interacting Mainly With a C-C Chemokine Receptor, CCR1*. Blood, 1997. **90**(2): p. 605-611.
51. Clemetson, K.J., et al., *Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets*. Blood, 2000. **96**(13): p. 4046-54.
52. Ribeiro, S. and R. Horuk, *The clinical potential of chemokine receptor antagonists*. Pharmacol Ther, 2005. **107**(1): p. 44-58.
53. Wells, T.N., et al., *Chemokine blockers--therapeutics in the making?* Trends Pharmacol Sci, 2006. **27**(1): p. 41-7.
54. Reichel, C.A., et al., *Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue*. J Leukoc Biol, 2006. **79**(1): p. 114-22.
55. Broxmeyer, H.E., et al., *Dominant myelopoietic effector functions mediated by chemokine receptor CCR1*. J Exp Med, 1999. **189**(12): p. 1987-92.
56. Rodriguez-Sosa, M., et al., *CC chemokine receptor 1 enhances susceptibility to Leishmania major during early phase of infection*. Immunol Cell Biol, 2003. **81**(2): p. 114-20.
57. Topham, P.S., et al., *Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis*. J Clin Invest, 1999. **104**(11): p. 1549-57.
58. Zerneck, A., et al., *Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10*. Blood, 2006. **107**(11): p. 4240-3.
59. Atchison, R.E., et al., *Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines*. Science, 1996. **274**(5294): p. 1924-1926.
60. Khan, I.A., et al., *CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection*. PLoS Pathog, 2006. **2**(6): p. e49.
61. Loetscher, P., et al., *CCR5 is characteristic of Th1 lymphocytes*. Nature, 1998. **391**(6665): p. 344-345.
62. N. Ødum, S.B., K.W. Eriksen, S. Skov, L.P. Ryder, K. Bendtzen, R.J.J. Van Neerven, A. Svejgaard, P. Garred,, *The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells*. Tissue Antigens, 1999. **54**(6): p. 572-577.
63. Barbonetti, A., et al., *RANTES and human sperm fertilizing ability: effect on acrosome reaction and sperm/oocyte fusion*. Mol. Hum. Reprod., 2008. **14**(7): p. 387-391.
64. Isobe, T., et al., *The effect of RANTES on human sperm chemotaxis*. Hum. Reprod., 2002. **17**(6): p. 1441-1446.
65. Muciaccia, B., et al., *Beta-chemokine receptors 5 and 3 are expressed on the head region of human spermatozoon*. FASEB J, 2005. **19**(14): p. 2048-50.
66. Choudhary, S.K., et al., *R5 Human Immunodeficiency Virus Type 1 Infection of Fetal Thymic Organ Culture Induces Cytokine and CCR5 Expression*. J. Virol., 2005. **79**(1): p. 458-471.

67. Houle, M., *et al.*, *IL-10 up-regulates CCR5 gene expression in human monocytes*. *Inflammation*, 1999. **23**(3): p. 241-51.
68. Sato, K., *et al.*, *TGF- β 1 Reciprocally Controls Chemotaxis of Human Peripheral Blood Monocyte-Derived Dendritic Cells Via Chemokine Receptors*. *J Immunol*, 2000. **164**(5): p. 2285-2295.
69. Hill, S.J., *G-protein-coupled receptors: past, present and future*. *Br J Pharmacol*, 2006. **147 Suppl 1**: p. S27-37.
70. Gulick, R.M., *et al.*, *Maraviroc for Previously Treated Patients with R5 HIV-1 Infection*. *N Engl J Med*, 2008. **359**(14): p. 1429-1441.
71. Sax, P.E., *FDA approval: maraviroc*. *AIDS Clin Care*, 2007. **19**(9): p. 75.
72. Horuk, R., *Chemokine receptor antagonists: overcoming developmental hurdles*. *Nat Rev Drug Discov*, 2009. **8**(1): p. 23-33.
73. Huffnagle, G.B., *et al.*, *Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans*. *J Immunol*, 1999. **163**(9): p. 4642-6.
74. Luangsay, S., *et al.*, *CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells*. *Gastroenterology*, 2003. **125**(2): p. 491-500.
75. Machado, F.S., *et al.*, *CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi*. *J Infect Dis*, 2005. **191**(4): p. 627-36.
76. Yurchenko, E., *et al.*, *CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence*. *J Exp Med*, 2006. **203**(11): p. 2451-60.
77. Glass, W.G., *et al.*, *Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus*. *Virology*, 2001. **288**(1): p. 8-17.
78. Glass, W.G. and T.E. Lane, *Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8+ T cells following coronavirus infection of the central nervous system*. *Virology*, 2003. **312**(2): p. 407-14.
79. Glass, W.G., *et al.*, *Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection*. *J Exp Med*, 2005. **202**(8): p. 1087-98.
80. Tyner, J.W., *et al.*, *CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection*. *Nat Med*, 2005. **11**(11): p. 1180-7.
81. Ma, B., *et al.*, *Role of CCR5 in IFN-gamma-induced and cigarette smoke-induced emphysema*. *J Clin Invest*, 2005. **115**(12): p. 3460-72.
82. Alkhatib, G., *et al.*, *CC CKR5: A RANTES, MIP-1alpha, MIP-1beta Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1*. *Science*, 1996. **272**(5270): p. 1955-1958.
83. Choe, H., *et al.*, *The [beta]-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates*. *Cell*, 1996. **85**(7): p. 1135-1148.
84. Deng, H., *et al.*, *Identification of a major co-receptor for primary isolates of HIV-1*. *Nature*, 1996. **381**(6584): p. 661-666.
85. Doranz, B.J., *et al.*, *A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the [beta]-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors*. *Cell*, 1996. **85**(7): p. 1149-1158.
86. Dragic, T., *et al.*, *HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5*. *Nature*, 1996. **381**(6584): p. 667-673.
87. Feng, Y., *et al.*, *HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor*. *Science*, 1996. **272**(5263): p. 872-877.
88. Deng, H., *et al.*, *Expression cloning of new receptors used by simian and human immunodeficiency viruses*. *Nature*, 1997. **388**(6639): p. 296-300.

-
89. Liao, F., et al., *STRL33, A Novel Chemokine Receptor-like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line-tropic HIV-1*. J. Exp. Med., 1997. **185**(11): p. 2015-2023.
 90. Pleskoff, O., et al., *Identification of a Chemokine Receptor Encoded by Human Cytomegalovirus as a Cofactor for HIV-1 Entry*. Science, 1997. **276**(5320): p. 1874-1878.
 91. Weissman, D., et al., *Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor*. Nature, 1997. **389**(6654): p. 981-5.
 92. Xiao, X., et al., *Constitutive cell surface association between CD4 and CCR5*. Proc Natl Acad Sci U S A, 1999. **96**(13): p. 7496-501.
 93. Lynch, E.A., et al., *Cutting Edge: IL-16/CD4 Preferentially Induces Th1 Cell Migration: Requirement of CCR5*. J Immunol, 2003. **171**(10): p. 4965-4968.
 94. Staudinger, R., et al., *Evidence for CD4-enhanced signaling through the chemokine receptor CCR5*. J Biol Chem, 2003. **278**(12): p. 10389-92.
 95. Cocchi, F., et al., *Identification of RANTES, MIP-1alpha, and MIP-1beta as the Major HIV-Suppressive Factors Produced by CD8+ T Cells*. Science, 1995. **270**(5243): p. 1811-1815.
 96. Garred, P. and J. Eugen-Olsen, *Dual effect of CCR5 Delta 32 gene deletion in HIV-1 infected patients*. Lancet, 1997. **349**(9069): p. 1884.
 97. Hall, I.P., et al., *Association of CCR5 delta32 with reduced risk of asthma*. Lancet, 1999. **354**(9186): p. 1264-5.
 98. Zimmerman, P.A., et al., *Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk*. Mol Med, 1997. **3**(1): p. 23-36.
 99. Faure, E. and M. Royer-Carenzi, *Is the European spatial distribution of the HIV-1-resistant CCR5-[Delta]32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?* Infection, Genetics and Evolution, 2008. **8**(6): p. 864-874.
 100. Sabeti, P.C., et al., *The Case for Selection at CCR5delta32*. PLoS Biology, 2005. **3**(11): p. e378.
 101. Nelson, P.J. and A.M. Krensky, *Chemokines, chemokine receptors, and allograft rejection*. Immunity, 2001. **14**(4): p. 377-86.
 102. Gao, W., et al., *Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection*. J Clin Invest, 2000. **105**(1): p. 35-44.
 103. Hamrah, P., et al., *Deletion of the Chemokine Receptor CCR1 Prolongs Corneal Allograft Survival*. Invest. Ophthalmol. Vis. Sci., 2007. **48**(3): p. 1228-1236.
 104. J. Bedke, E.K., L. Schaefer, C.-L. Behnes, M. Bonrouhi, N. Gretz, R. Horuk, M. Diedrichs-Moehring, G. Wildner, P. J. Nelson, H.J. Gröne,, *Beneficial Effects of CCR1 Blockade on the Progression of Chronic Renal Allograft Damage*. American Journal of Transplantation, 2007. **7**(3): p. 527-537.
 105. Horuk, R., et al., *CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model*. Immunology Letters, 2001. **76**(3): p. 193-201.
 106. Proudfoot, A.E., et al., *Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist*. J Biol Chem, 1996. **271**(5): p. 2599-603.
 107. Yun, J.J., et al., *Combined Blockade of the Chemokine Receptors CCR1 and CCR5 Attenuates Chronic Rejection*. Circulation, 2004. **109**(7): p. 932-937.
 108. Gröne, H.J., et al., *Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment*. FASEB J, 1999. **13**(11): p. 1371-83.
 109. Akashi, S., et al., *A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection*. Transplantation, 2005. **80**(3): p. 378-84.
 110. Xu, H., et al., *Effects of blocking the chemokine receptors, CCR5 and CXCR3, With TAK-779 in a rat small intestinal transplantation model*. Transplantation, 2008. **86**(12): p. 1810-7.

111. Gao, W., *et al.*, *Beneficial effects of targeting CCR5 in allograft recipients*. *Transplantation*, 2001. **72**(7): p. 1199-205.
112. Luckow, B., *et al.*, *Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice*. *Eur J Immunol*, 2004. **34**(9): p. 2568-78.
113. Amano, H., *et al.*, *Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts*. *J Immunol*, 2005. **174**(10): p. 6499-508.
114. Bickerstaff, A., *et al.*, *Acute humoral rejection of renal allografts in CCR5(-/-) recipients*. *Am J Transplant*, 2008. **8**(3): p. 557-66.
115. Schnickel, G.T., *et al.*, *Role of CXCR3 and CCR5 in Allograft Rejection*. *Transplantation Proceedings*, 2006. **38**(10): p. 3221-3224.
116. Schroppe, B., *et al.*, *Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways*. *J Am Soc Nephrol*, 2004. **15**(7): p. 1853-61.
117. Abdi, R., *et al.*, *The Role of CC Chemokine Receptor 5 (CCR5) in Islet Allograft Rejection*. *Diabetes*, 2002. **51**(8): p. 2489-2495.
118. Yi, S., *et al.*, *Involvement of CCR5 signaling in macrophage recruitment to porcine islet xenografts*. *Transplantation*, 2005. **80**(10): p. 1468-75.
119. Murai, M., *et al.*, *Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction*. *Nat Immunol*, 2003. **4**(2): p. 154-60.
120. Welniak, L.A., *et al.*, *An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease*. *Exp Hematol*, 2004. **32**(3): p. 318-24.
121. Wysocki, C.A., *et al.*, *Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning*. *J Immunol*, 2004. **173**(2): p. 845-54.
122. Wysocki, C.A., *et al.*, *Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease*. *Blood*, 2005. **106**(9): p. 3300-7.
123. Kallikourdis, M., *et al.*, *Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus*. *Proc Natl Acad Sci U S A*, 2007. **104**(2): p. 594-9.
124. Jones, D.B., *Glomerulonephritis*. *Am J Pathol*, 1953. **29**(1): p. 33-51.
125. Segerer, S., *et al.*, *Expression of chemokines and chemokine receptors during human renal transplant rejection*. *Am J Kidney Dis*, 2001. **37**(3): p. 518-31.
126. Syrbe, U., J. Siveke, and A. Hamann, *Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?* *Springer Semin Immunopathol*, 1999. **21**(3): p. 263-85.
127. Segerer, S., P.J. Nelson, and D. Schlondorff, *Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies*. *J Am Soc Nephrol*, 2000. **11**(1): p. 152-76.
128. Yun, J.J., *et al.*, *Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy*. *Transplantation*, 2000. **69**(12): p. 2515-24.
129. Shimizu, K. and R.N. Mitchell, *The Role of Chemokines in Transplant Graft Arterial Disease*. *Arterioscler Thromb Vasc Biol*, 2008. **28**(11): p. 1937-1949.
130. Pattison, J., *et al.*, *RANTES chemokine expression in cell-mediated transplant rejection of the kidney*. *Lancet*, 1994. **343**(8891): p. 209-11.
131. Ode-Hakim, S., *et al.*, *Delayed-type hypersensitivity-like mechanisms dominate late acute rejection episodes in renal allograft recipients*. *Transplantation*, 1996. **61**(8): p. 1233-40.
132. D'Elios, M.M., *et al.*, *Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts*. *Kidney Int*, 1997. **51**(6): p. 1876-84.
133. Oliveira, G., *et al.*, *Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection*. *Nephrol Dial Transplant*, 1998. **13**(2): p. 417-22.

-
134. Ruster, M., *et al.*, *Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts*. Clin Nephrol, 2004. **61**(1): p. 30-9.
 135. Mayer, V., *et al.*, *Expression of the chemokine receptor CCR1 in human renal allografts*. Nephrol. Dial. Transplant., 2007. **22**(6): p. 1720-1729.
 136. Tauber, A., Chernyak, L, *Metchnikoff and the origins of immunology: from metaphor to theory*. Monographs on the history and philosophy of biology. 1991 New York: Oxford University Press.
 137. Gordon, S., *Elie Metchnikoff: Father of natural immunity*. European Journal of Immunology, 2008. **38**(12): p. 3257-3264.
 138. van Furth, R., *et al.*, *The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells*. Bull World Health Organ, 1972. **46**(6): p. 845-52.
 139. Fogg, D.K., *et al.*, *A clonogenic bone marrow progenitor specific for macrophages and dendritic cells*. Science, 2006. **311**(5757): p. 83-7.
 140. Ziegler-Heitbrock, H., *Definition of human blood monocytes*. J Leukoc Biol, 2000. **67**(5): p. 603-606.
 141. Gordon, S. and P.R. Taylor, *Monocyte and macrophage heterogeneity*. Nat Rev Immunol, 2005. **5**(12): p. 953-64.
 142. Tacke, F. and G.J. Randolph, *Migratory fate and differentiation of blood monocyte subsets*. Immunobiology, 2006. **211**(6-8): p. 609-618.
 143. Varol, C., S. Yona, and S. Jung, *Origins and tissue-context-dependent fates of blood monocytes*. Immunol Cell Biol, 2008. **87**(1): p. 30-38.
 144. Hume, D.A., *Macrophages as APC and the Dendritic Cell Myth*. J Immunol, 2008. **181**(9): p. 5829-5835.
 145. Rabinovitch, M., *Professional and non-professional phagocytes: an introduction*. Trends Cell Biol, 1995. **5**(3): p. 85-7.
 146. Aderem, A. and D.M. Underhill, *Mechanisms of phagocytosis in macrophages*. Annual Review of Immunology, 1999. **17**(1): p. 593.
 147. Indik, Z.K., *et al.*, *The molecular dissection of Fc gamma receptor mediated phagocytosis*. Blood, 1995. **86**(12): p. 4389-99.
 148. Janeway, C.A., Jr., *The immune system evolved to discriminate infectious nonself from noninfectious self*. Immunol Today, 1992. **13**(1): p. 11-6.
 149. Meylan, E., J.r. Tschopp, and M. Karin, *Intracellular pattern recognition receptors in the host response*. Nature, 2006. **442**(7098): p. 39-44.
 150. Gordon, S., *The macrophage: past, present and future*. Eur J Immunol, 2007. **37** Suppl 1: p. S9-17.
 151. Martinez, F.O., *et al.*, *Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression*. J Immunol, 2006. **177**(10): p. 7303-11.
 152. Mosmann, T.R., *et al.*, *Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins*. J Immunol, 1986. **136**(7): p. 2348-57.
 153. Mosmann, T.R. and R.L. Coffman, *TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties*. Annu Rev Immunol, 1989. **7**: p. 145-73.
 154. Romagnani, S., *Th1/Th2 cells*. Inflamm Bowel Dis, 1999. **5**(4): p. 285-94.
 155. Martinez, F.O., *et al.*, *Macrophage activation and polarization*. Front Biosci, 2008. **13**: p. 453-61.
 156. Gordon, S., *Alternative activation of macrophages*. Nat Rev Immunol, 2003. **3**(1): p. 23-35.
 157. Mantovani, A., *et al.*, *The chemokine system in diverse forms of macrophage activation and polarization*. Trends in Immunology, 2004. **25**(12): p. 677-686.
 158. Klimp, A.H., *et al.*, *A potential role of macrophage activation in the treatment of cancer*. Critical Reviews in Oncology/Hematology, 2002. **44**(2): p. 143-161.
-

159. Stein, M., *et al.*, *Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation*. *J Exp Med*, 1992. **176**(1): p. 287-92.
160. Martinez, F.O., L. Helming, and S. Gordon, *Alternative Activation of Macrophages: An Immunologic Functional Perspective*. *Annu Rev Immunol*, 2008.
161. Maggi, E., *The TH1/TH2 paradigm in allergy*. *Immunotechnology*, 1998. **3**(4): p. 233-44.
162. Brandt, E., *et al.*, *IL-4 production by human polymorphonuclear neutrophils*. *J Leukoc Biol*, 2000. **68**(1): p. 125-30.
163. Mosser, D.M. and J.P. Edwards, *Exploring the full spectrum of macrophage activation*. *Nat Rev Immunol*, 2008. **8**(12): p. 958-69.
164. Porcheray, F., *et al.*, *Macrophage activation switching: an asset for the resolution of inflammation*. *Clin Exp Immunol*, 2005. **142**(3): p. 481-9.
165. Gratchev, A., *et al.*, *M[phi]1 and M[phi]2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals*. *Immunobiology*, 2006. **211**(6-8): p. 473-486.
166. Stout, R.D., *et al.*, *Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences*. *J Immunol*, 2005. **175**(1): p. 342-9.
167. Yardimci, N., *et al.*, *Neurologic complications after renal transplant*. *Exp Clin Transplant*, 2008. **6**(3): p. 224-8.
168. Tejani, A. and L. Emmett, *Acute and chronic rejection*. *Semin Nephrol*, 2001. **21**(5): p. 498-507.
169. Knoll, G., *Trends in kidney transplantation over the past decade*. *Drugs*, 2008. **68 Suppl 1**: p. 3-10.
170. O. Cheng, R.T., E. Sampson, G. Schultz, P. Ruiz, X. Zhang, P.S.T. Yuen, R.B. Mannon,, *Connective Tissue Growth Factor is a Biomarker and Mediator of Kidney Allograft Fibrosis*. *American Journal of Transplantation*, 2006. **6**(10): p. 2292-2306.
171. Niimi, M., *The technique for heterotopic cardiac transplantation in mice: experience of 3000 operations by one surgeon*. *J Heart Lung Transplant*, 2001. **20**(10): p. 1123-8.
172. Zhang, Z., *et al.*, *Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations*. *Transplantation*, 1996. **62**(9): p. 1267-72.
173. Abdi, R., *et al.*, *Differential Role of CCR2 in Islet and Heart Allograft Rejection: Tissue Specificity of Chemokine/Chemokine Receptor Function In Vivo*. *J Immunol*, 2004. **172**(2): p. 767-775.
174. Haskova, Z., *et al.*, *Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection*. *Transplantation*, 2007. **83**(12): p. 1595-601.
175. Stasikowska, O. and M. Wagrowska-Danilewicz, *Chemokines and chemokine receptors in glomerulonephritis and renal allograft rejection*. *Med Sci Monit*, 2007. **13**(2): p. RA31-6.
176. Wong, M.M. and E.N. Fish, *Chemokines: attractive mediators of the immune response*. *Semin Immunol*, 2003. **15**(1): p. 5-14.
177. Luther, S.A. and J.G. Cyster, *Chemokines as regulators of T cell differentiation*. *Nat Immunol*, 2001. **2**(2): p. 102-7.
178. Lee, C., *et al.*, *Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways*. *J Leukoc Biol*, 2003. **74**(5): p. 676-682.
179. Gao, J.L., *et al.*, *Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1*. *J Exp Med*, 1997. **185**(11): p. 1959-68.
180. Senger, M., *et al.*, *X-HUSAR, an X-based graphical interface for the analysis of genomic sequences*. *Comput Methods Programs Biomed*, 1995. **46**(2): p. 131-41.
181. Rozen, S. and H. Skaletsky, *Primer3 on the WWW for general users and for biologist programmers*. *Methods Mol Biol*, 2000. **132**: p. 365-86.
182. Cui, W., D.D. Taub, and K. Gardner, *qPrimerDepot: a primer database for quantitative real time PCR*. *Nucleic Acids Res*, 2007. **35**(Database issue): p. D805-9.

-
183. Zhang, Z., *et al.*, *Improved techniques for kidney transplantation in mice*. *Microsurgery*, 1995. **16**(2): p. 103-9.
184. Kiss, E., *et al.*, *Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection*. *Transplantation*, 2003. **76**(3): p. 480-9.
185. Adams, J., *et al.*, *13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy*. *Am J Pathol*, 2005. **167**(1): p. 285-98.
186. Ward, J.M., *et al.*, *Hyalinosis and Ym1/Ym2 gene expression in the stomach and respiratory tract of 129S4/SvJae and wild-type and CYP1A2-null B6, 129 mice*. *Am J Pathol*, 2001. **158**(1): p. 323-32.
187. Pfaffl, M.W., *A new mathematical model for relative quantification in real-time RT-PCR*. *Nucleic Acids Res*, 2001. **29**(9): p. e45.
188. Hopken, U.E., *et al.*, *The chemokine receptor CCR7 controls lymph node-dependent cytotoxic T cell priming in alloimmune responses*. *Eur J Immunol*, 2004. **34**(2): p. 461-70.
189. Gillies, S.D., *et al.*, *A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene*. *Cell*, 1983. **33**(3): p. 717-28.
190. Corraliza, I.M., *et al.*, *Determination of arginase activity in macrophages: a micromethod*. *J Immunol Methods*, 1994. **174**(1-2): p. 231-5.
191. Munder, M., *et al.*, *Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells*. *J Immunol*, 1999. **163**(7): p. 3771-7.
192. Doschko, G.U.M., *Untersuchungen zur Regulation des Enzyms Arginase in humanen Granulozyten, in Arbeitsgruppe Immunologie der Tierärztlichen Hochschule Hannover und dem Deutschen Krebsforschungszentrum Heidelberg (Kooperationseinheit Molekulare Hämatologie und Onkologie, Medizinische Klinik und Poliklinik V der Universität Heidelberg)*. 2004, Tierärztliche Hochschule Hannover: Hannover. p. 183.
193. Gersuk, G.M., L.W. Razai, and K.A. Marr, *Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1*. *Journal of Immunological Methods*, 2008. **329**(1-2): p. 157-166.
194. Ladner, M.B., *et al.*, *cDNA cloning and expression of murine macrophage colony-stimulating factor from L929 cells*. *Proc Natl Acad Sci U S A*, 1988. **85**(18): p. 6706-10.
195. Boltz-Nitulescu, G., *et al.*, *Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant*. *J Leukoc Biol*, 1987. **41**(1): p. 83-91.
196. Cowden, R.R. and S.K. Curtis, *Microfluorometric investigations of chromatin structure. I. Evaluation of nine DNA-specific fluorochromes as probes of chromatin organization*. *Histochemistry*, 1981. **72**(1): p. 11-23.
197. Schmid, I., *et al.*, *Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry*. *Cytometry*, 1992. **13**(2): p. 204-8.
198. Daeron, M., *Fc receptor biology*. *Annu Rev Immunol*, 1997. **15**: p. 203-34.
199. Deka, C., *et al.*, *Analysis of fluorescence lifetime and quenching of FITC-conjugated antibodies on cells by phase-sensitive flow cytometry*. *Cytometry*, 1996. **25**(3): p. 271-9.
200. Silbernagl, S., Despopoulos, A., *Taschenatlas der Physiologie*. 4., überarbeitete Auflage ed. 1991: Georg Thieme Verlag. 371.
201. Luster, A.D., *The role of chemokines in linking innate and adaptive immunity*. *Curr Opin Immunol*, 2002. **14**(1): p. 129-35.
202. Serbina, N.V. and E.G. Pamer, *Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2*. *Nat Immunol*, 2006. **7**(3): p. 311-7.
203. Gaffen, S.L. and K.D. Liu, *Overview of interleukin-2 function, production and clinical applications*. *Cytokine*, 2004. **28**(3): p. 109-123.
204. Mathan, A., S. Kuruvilla, and G. Abraham, *Interleukin 2 receptor expression in renal biopsies and the diagnosis of acute allograft rejection*. Vol. 49. 2006. 12-6.
-

205. Siveke, J.T. and A. Hamann, *T helper 1 and T helper 2 cells respond differentially to chemokines*. J Immunol, 1998. **160**(2): p. 550-4.
206. Sundrud, M.S., et al., *Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation*. J Immunol, 2003. **171**(7): p. 3542-9.
207. Hebenstreit, D., et al., *Signaling mechanisms, interaction partners, and target genes of STAT6*. Cytokine Growth Factor Rev, 2006. **17**(3): p. 173-88.
208. Afzali, B., et al., *The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease*. Clin Exp Immunol, 2007. **148**(1): p. 32-46.
209. Chen, Y. and K.J. Wood, *Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection?* Transplantation, 2007. **84**(9): p. 1071-4.
210. Iwakura, Y. and H. Ishigame, *The IL-23/IL-17 axis in inflammation*. J Clin Invest, 2006. **116**(5): p. 1218-22.
211. Veldhoen, M. and B. Stockinger, *TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells*. Trends Immunol, 2006. **27**(8): p. 358-61.
212. Ensminger, S.M., et al., *Increased transplant arteriosclerosis in the absence of CCR7 is associated with reduced expression of Foxp3*. Transplantation, 2008. **86**(4): p. 590-600.
213. Forster, R., A.C. Davalos-Misnitz, and A. Rot, *CCR7 and its ligands: balancing immunity and tolerance*. Nat Rev Immunol, 2008. **8**(5): p. 362-71.
214. Lee, I., et al., *Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor*. J Exp Med, 2005. **201**(7): p. 1037-44.
215. Kahnert, A., et al., *Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis*. Eur J Immunol, 2006. **36**(3): p. 631-47.
216. Mantovani, A., et al., *Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes*. Trends Immunol, 2002. **23**(11): p. 549-55.
217. Potter, P.K., et al., *Lupus-Prone Mice Have an Abnormal Response to Thioglycolate and an Impaired Clearance of Apoptotic Cells*. J Immunol, 2003. **170**(6): p. 3223-3232.
218. Cook, A.D., E.L. Braine, and J.A. Hamilton, *The phenotype of inflammatory macrophages is stimulus dependent: implications for the nature of the inflammatory response*. J Immunol, 2003. **171**(9): p. 4816-23.
219. Munder, M., K. Eichmann, and M. Modolell, *Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype*. J Immunol, 1998. **160**(11): p. 5347-54.
220. Munder, P.G., M. Modolell, and D.F.H. Wallach, *Cell propagation on films of polymeric fluorocarbon as a means to regulate pericellular pH and pO₂ in cultured monolayers*. Febs Letters, 1971. **15**(3): p. 191-&.
221. van der Meer, J.W.M., et al., *Suspension cultures of mononuclear phagocytes in the Teflon culture bag*. Cellular Immunology, 1979. **42**(1): p. 208-212.
222. Modolell, M., et al., *Killing of Borrelia burgdorferi by macrophages is dependent on oxygen radicals and nitric oxide and can be enhanced by antibodies to outer surface proteins of the spirochete*. Immunology Letters, 1994. **40**(2): p. 139-146.
223. Zou, W., et al., *Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12*. J Immunol, 2000. **165**(8): p. 4388-96.
224. Russell, P.S., et al., *Induced immune destruction of long-surviving, H-2 incompatible kidney transplants in mice*. J Exp Med, 1978. **147**(5): p. 1469-86.
225. Fischereder, M., *Chemokines and chemokine receptors in renal transplantation--from bench to bedside*. Acta Physiol Hung, 2007. **94**(1-2): p. 67-81.
226. Calo, L., et al., *Oxidative stress and nitric oxide system in post-transplant hypertension*. Clin Nephrol, 2000. **53**(4): p. suppl 6-7.

-
227. Matthias Mack, J.P., Christian Weber, Kim S.C. Weber, Peter J. Nelson, Tamara Rupp, Konstantin Maletz, Hilke Brühl, Detlef Schlöndorff, *Chondroitin sulfate A released from platelets blocks RANTES presentation on cell surfaces and RANTES-dependent firm adhesion of leukocytes*. European Journal of Immunology, 2002. **32**(4): p. 1012-1020.
228. Weber, C., et al., *Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells*. Blood, 2001. **97**(4): p. 1144-6.
229. Moser, B., et al., *Chemokines: multiple levels of leukocyte migration control*. Trends Immunol, 2004. **25**(2): p. 75-84.
230. Lakkis, F.G., et al., *Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue*. Nat Med, 2000. **6**(6): p. 686-8.
231. Sallusto, F. and A. Lanzavecchia, *Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression*. Immunol Rev, 2000. **177**: p. 134-40.
232. Cools, N., et al., *Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells*. J Leukoc Biol, 2007. **82**(6): p. 1365-1374.
233. Cook, C.H., et al., *Spontaneous Renal Allograft Acceptance Associated with "Regulatory" Dendritic Cells and IDO*. J Immunol, 2008. **180**(5): p. 3103-3112.
234. Turner, J.E., et al., *Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases*. Mini Rev Med Chem, 2007. **7**(11): p. 1089-96.
235. Bromley, S.K., T.R. Mempel, and A.D. Luster, *Orchestrating the orchestrators: chemokines in control of T cell traffic*. Nat Immunol, 2008. **9**(9): p. 970-80.
236. Geissmann, F., S. Jung, and D.R. Littman, *Blood monocytes consist of two principal subsets with distinct migratory properties*. Immunity, 2003. **19**(1): p. 71-82.
237. Fantuzzi, L., et al., *Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response*. Blood, 1999. **94**(3): p. 875-83.
238. Wang, J., et al., *Cytokine Regulation of Human Immunodeficiency Virus Type 1 Entry and Replication in Human Monocytes/Macrophages through Modulation of CCR5 Expression*. J. Virol., 1998. **72**(9): p. 7642-7647.
239. Sozzani, S., et al., *Interleukin 10 increases CCR5 expression and HIV infection in human monocytes*. J Exp Med, 1998. **187**(3): p. 439-44.
240. Shurin, M.R., et al., *Th1/Th2 balance in cancer, transplantation and pregnancy*. Springer Semin Immunopathol, 1999. **21**(3): p. 339-59.
241. Benghiat, F.S., et al., *Interleukin 17-producing T helper cells in alloimmunity*. Transplantation Reviews, 2009. **23**(1): p. 11-18.
242. Piccotti, J.R., et al., *Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival?* Transplantation, 1997. **63**(5): p. 619-24.
243. Le Moine, A. and M. Goldman, *Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction?* Am J Transplant, 2003. **3**(2): p. 101-6.
244. Chan, S.Y., et al., *In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection*. Transplantation, 1995. **59**(8): p. 1155-61.
245. Guillonau, C., et al., *CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase*. J Clin Invest, 2007. **117**(4): p. 1096-106.
246. Sawitzki, B., et al., *IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo*. J Exp Med, 2005. **201**(12): p. 1925-35.
247. Thebault, P., et al., *Role of IFN-gamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells*. Am J Transplant, 2007. **7**(11): p. 2472-82.
248. Wood, K.J., et al., *Interferon gamma: friend or foe?* Transplantation, 2007. **84**(1 Suppl): p. S4-5.
249. Chen, L., et al., *TLR engagement prevents transplantation tolerance*. Am J Transplant, 2006. **6**(10): p. 2282-91.
-

250. David M. Miller, T.T., Todd Pearson, Masahiro Yamazaki, Michael A. Brehm, Aldo A. Rossini, Dale L. Greiner, *TLR Agonists Abrogate Co-stimulation Blockade-Induced Mixed Chimerism and Transplantation Tolerance*. Annals of the New York Academy of Sciences, 2008. **1150**(Immunology of Diabetes V From Bench to Bedside): p. 149-151.
251. Porrett, P.M., *et al.*, *Mechanisms Underlying Blockade of Allograft Acceptance by TLR Ligands*. J Immunol, 2008. **181**(3): p. 1692-1699.
252. Miura, M., T. El-Sawy, and R.L. Fairchild, *Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma*. Am J Pathol, 2003. **162**(2): p. 509-19.
253. Li, J., *et al.*, *Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model*. Eur J Cardiothorac Surg, 2006. **29**(5): p. 779-83.
254. Antonysamy, M.A., *et al.*, *Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors*. J Immunol, 1999. **162**(1): p. 577-84.
255. Antonysamy, M.A., *et al.*, *Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival*. Transplant Proc, 1999. **31**(1-2): p. 93.
256. Bettelli, E., *et al.*, *Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells*. Nature, 2006. **441**(7090): p. 235-8.
257. Russell, P.S., *et al.*, *Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants*. J Exp Med, 1978. **147**(5): p. 1449-68.
258. Bickerstaff, A.A., *et al.*, *The graft helps to define the character of the alloimmune response*. Transpl Immunol, 2002. **9**(2-4): p. 137-41.
259. Schneider, M.A., *et al.*, *CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells*. J Exp Med, 2007. **204**(4): p. 735-45.
260. Lohr, J., *et al.*, *Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease*. J Exp Med, 2006. **203**(13): p. 2785-91.
261. Veldhoen, M., *et al.*, *TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells*. Immunity, 2006. **24**(2): p. 179-89.
262. Xu, L., *et al.*, *Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta*. J Immunol, 2007. **178**(11): p. 6725-9.
263. Eis, V., *et al.*, *Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction*. J Am Soc Nephrol, 2004. **15**(2): p. 337-47.
264. Ramos, C.D.L., *et al.*, *MIP-1{alpha}[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-{alpha} and LTB4*. J Leukoc Biol, 2005. **78**(1): p. 167-177.
265. Gladue, R.P., *et al.*, *The Human Specific CCR1 Antagonist CP-481,715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice*. J Immunol, 2006. **176**(5): p. 3141-3148.
266. O'Garra, A. and P. Vieira, *T(H)1 cells control themselves by producing interleukin-10*. Nat Rev Immunol, 2007. **7**(6): p. 425-8.
267. Andres, P.G., *et al.*, *Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine*. J Immunol, 2000. **164**(12): p. 6303-12.
268. Famulski, K.S., Sis, B., Billesberger, L., Halloran, P. F., *Interferon-gamma and Donor MHC Class I Control Alternative Macrophage Activation and Activin Expression in Rejecting Kidney Allografts: A Shift in the Th1-Th2 Paradigm*. American Journal of Transplantation, 2008. **8**(3): p. 547-556.

-
269. Grau, V., B. Herbst, and B. Steiniger, *Dynamics of monocytes/macrophages and T lymphocytes in acutely rejecting rat renal allografts*. Cell Tissue Res, 1998. **291**(1): p. 117-26.
270. Wyburn, K.R., et al., *The role of macrophages in allograft rejection*. Transplantation, 2005. **80**(12): p. 1641-7.
271. Le Meur, Y., et al., *Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway*. J Leukoc Biol, 2002. **72**(3): p. 530-7.
272. Le Meur, Y., et al., *Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection*. Transplantation, 2002. **73**(8): p. 1318-24.
273. Surquin, M., et al., *Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates*. J Immunol, 2002. **169**(1): p. 500-6.
274. Surquin, M., et al., *IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts*. Transplantation, 2005. **80**(10): p. 1485-92.
275. Goldman, M., et al., *A role for eosinophils in transplant rejection*. Trends in Immunology, 2001. **22**(5): p. 247-251.
276. Hogan, S., Rosenberg, H., Moqbel, R., Phipps, S., Foster, P., Lacy, P., Kay, A., Rothenberg, M., *Eosinophils: Biological Properties and Role in Health and Disease*. Clinical & Experimental Allergy, 2008. **38**(5): p. 709-750.
277. Luckow, B., et al., *Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice*. Eur J Immunol, 2004. **34**(9): p. 2568-78.
278. Hansson, G.K. and P. Libby, *The immune response in atherosclerosis: a double-edged sword*. Nat Rev Immunol, 2006. **6**(7): p. 508-19.
279. Braunersreuther, V., et al., *Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice*. Arterioscler Thromb Vasc Biol, 2007. **27**(2): p. 373-9.
280. Cornell, L.D., R.N. Smith, and R.B. Colvin, *Kidney Transplantation: Mechanisms of Rejection and Acceptance*. Annual Review of Pathology: Mechanisms of Disease, 2008. **3**(1): p. 189.
281. Kunkel, S.L. and N. Godessart, *Chemokines in autoimmunity: from pathology to therapeutics*. Autoimmun Rev, 2002. **1**(6): p. 313-20.
282. Proudfoot A., P.C., Wells T.,, *The strategy of blocking the chemokine system to combat disease*. Immunological Reviews, 2000. **177**(1): p. 246-256.
283. Haringman, J.J. and P.P. Tak, *Chemokine blockade: a new era in the treatment of rheumatoid arthritis?* Arthritis Res Ther, 2004. **6**(3): p. 93-7.
284. Proudfoot, A.E.I., *Chemokine receptors: multifaceted therapeutic targets*. Nat Rev Immunol, 2002. **2**(2): p. 106-115.
285. Lloyd, C.M., et al., *Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver*. Journal of Immunological Methods, 2008. **334**(1-2): p. 70-81.
286. Taylor, P.R., et al., *Macrophage receptors and immune recognition*. Annual Review of Immunology, 2005. **23**(1): p. 901.
287. Fadok, V.A., et al., *Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF*. J Clin Invest, 1998. **101**(4): p. 890-8.
288. Raes, G., et al., *Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages*. J Leukoc Biol, 2002. **71**(4): p. 597-602.
289. Raes, G., et al., *FIZZ1 and Ym as tools to discriminate between differentially activated macrophages*. Dev Immunol, 2002. **9**(3): p. 151-9.
-

290. Loke, P., *et al.*, *Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection.* J Immunol, 2007. **179**(6): p. 3926-36.
291. Schroder, C., *et al.*, *CCR5 blockade modulates inflammation and alloimmunity in primates.* J Immunol, 2007. **179**(4): p. 2289-99.
292. Heinzl, F.P., *et al.*, *Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.* J Exp Med, 1989. **169**(1): p. 59-72.
293. Mills, C.D., *et al.*, *M-1/M-2 macrophages and the Th1/Th2 paradigm.* J Immunol, 2000. **164**(12): p. 6166-73.
294. Brake, D.K., *et al.*, *ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice.* Am J Physiol Cell Physiol, 2006. **291**(6): p. C1232-1239.
295. Montecino-Rodriguez, E., H. Leathers, and K. Dorshkind, *Bipotent B-macrophage progenitors are present in adult bone marrow.* Nat Immunol, 2001. **2**(1): p. 83-88.
296. Tiemessen, M.M., *et al.*, *CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.* Proc Natl Acad Sci U S A, 2007. **104**(49): p. 19446-51.
297. Fang, F.C. and C.F. Nathan, *Man is not a mouse: reply.* J Leukoc Biol, 2007. **81**(3): p. 580.
298. Munder, M., *et al.*, *Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.* Blood, 2005. **105**(6): p. 2549-56.
299. Loong, C.C., *et al.*, *Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection.* J Pathol, 2002. **197**(3): p. 322-32.
300. Van Kooten, C., *et al.*, *Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection.* J Am Soc Nephrol, 1998. **9**(8): p. 1526-34.
301. B. M. Vanaudenaerde, S.I.D.V., R. Vos, I. Meyts, D. M. Bullens, V. Reynders, W. A. Wuyts, D. E. Van Raemdonck, L. J. Dupont, G. M. Verleden,, *The Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation.* American Journal of Transplantation, 2008. **8**(9): p. 1911-1920.
302. Di Marzio, P., *et al.*, *Role of Rho family GTPases in CCR1- and CCR5-induced actin reorganization in macrophages.* Biochemical and Biophysical Research Communications, 2005. **331**(4): p. 909-916.

